Zacks Investment Research on MSN
SRPT stock surges on promising early results from siRNA programs
Shares of Sarepta Therapeutics SRPT rose 35% on Wednesday after the company announced early clinical data on two experimental ...
Sarepta Therapeutics has shared initial clinical data on two siRNA candidates, delivering an early look at the wisdom of its ...
Sarepta (SRPT) stock rises on positive Phase 1/2 siRNA trial data showing muscle delivery, biomarker activity, and safety in ...
A formamide modification (yellow) to a therapeutic agent siRNA (blue) prevents siRNA to bind to non-target mRNA, which allows for treatment with less side effects. Small interfering RNA (siRNA) drugs ...
siMecA-AGO2 complex inhibits the translation of the mecA gene which encodes the penicillin-binding protein 2a (PBP2a), a protein at the heart of the drug-resistance phenotype in MRSA. By reducing ...
Jianhui Li of Wanhuida Intellectual Property reports on a ruling by the China National Intellectual Property Administration that could shed light on the patent examination standards concerning cutting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results